Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or eosinophilic duodenitis, according to a presentation at UEG Week. “Lirentelimab, previously called AK002, is a humanized monoclonal antibody that targets a receptor called siglec-8 that’s highly specific in eosinophils and mast cells. When this receptor is activated, it